Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433782 | 0.84 | TRPV1 (1.00) | TRPV1MEN1KMT2ANPC1PABPC1 | |
| SCHEMBL4430162 | 0.84 | TRPV1 (0.75) | TRPV1MEN1KMT2ANPC1PABPC1 | |
| SCHEMBL4433389 | 0.84 | TRPV1 (0.82) | TRPV1MEN1KMT2ANPC1PABPC1 | |
| SCHEMBL5934513 | 0.83 | NPC1 (0.58) | TRPV1MEN1KMT2ANPC1WNT3A | |
| SCHEMBL4427373 | 0.82 | TRPV1 (0.78) | TRPV1MEN1KMT2ANPC1PABPC1 | |
| SCHEMBL5934691 | 0.81 | NPC1 (0.61) | TRPV1MEN1KMT2ANPC1WNT3A | |
| SCHEMBL5934547 | 0.81 | PTPN1 (0.61) | MEN1KMT2ANPC1WNT3ARAB9A | |
| SCHEMBL5934584 | 0.81 | TRPV1 (0.58) | TRPV1MEN1KMT2ANPC1WNT3A | |
| SCHEMBL1543152 | 0.80 | KDM4E (0.60) | MEN1KMT2ANPC1WNT3ARAB9A | |
| SCHEMBL5934543 | 0.80 | NPC1 (0.54) | MEN1KMT2ANPC1WNT3ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480954-B1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | TRPV1 1/4885MEN1 3527/4885KMT2A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.